RecruitMe Clinical Trial

Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the BLADDER
ADAPT-BLADDER: Modern Immunotherpy in BCG-Relapsing Urothelial Carcinoma of the Bladder
Sponsor:Hoosier Cancer Research Network
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAR9652
U.S. Government ID:NCT03317158
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

This study is for patients who have bladder cancer that has not invaded muscle tissue and who have been treated with one or more surgical resections and Bacillus Calmette-Guerin or BCG, which was directly given into the bladder before. The main purpose of this trial is to show that durvalumab is safe when given alone, in combination with BCG treatments, and in combination with radiation therapy for patients whose bladder cancer has now come back. The overall goal of this trial is to see if the risk of the bladder cancer coming back can be decreased with this treatment regimen.

Do You Qualify?
Are you 18 years or older?YesNo
Are you willing and able to sign a consent form?YesNo
Did you receive a diagnosis of non-muscle invasive urothelial carcinoma of the bladder?YesNo
Submit
Cancel
Investigator
Christopher Anderson, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162